{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'Participant Name (Network sites use participant initials):', 'Medical Record No.: (Network sites use participant ID):', 'Title: A Randomized Multicenter Phase II Study Using 2-1 |Hexyloxyethyl|-2-', 'Devinylpyropheophorbide-A (HPPH) with PDT versus Standard of Care Surgery', 'for Patients with T1/T2 NO Squamous Cell Carcinoma of the Oral Cavity', 'EXCLUSION CRITERIA', 'Yes', 'No', 'N/A', 'All answers must be \"NO\" or \"N/A\" for participant enrollment', 'Date', '1. Those who have had chemotherapy or radiotherapy or targeted agents within', '4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the', 'study or those who have not recovered from adverse events due to agents', 'administered more than 4 weeks earlier.', '2.', 'Those with known brain metastases should be excluded from this clinical', 'trial because of their poor prognosis and because they often develop', 'progressive neurologic dysfunction that would confound the evaluation of', 'neurologic and other adverse events.', '3.', 'Those with porphyria or with known hypersensitivity to porphyrins or', 'porphyrin-like compounds.', '4.', 'WBC < 4,000.', '5.', 'Those with impaired renal and/or hepatic function, total serum', 'bilirubin > 2 mg/dL, serum creatinine > 2 mg/dL, alkaline phosphatase', '(hepatic) or SGOT > 3 times the upper normal limit.', '6.', 'Diagnostic biopsy reveals perineural invasion (PNI) and/or lymphovascular', 'invasion (LVI).', '7. Uncontrolled intercurrent illness including, but not limited to, ongoing or', 'active infection, symptomatic congestive heart failure, unstable angina', 'pectoris, cardiac arrhythmia, or psychiatric illness/social situations that', 'would limit compliance with study requirements.', '8. Nodal disease as detected by clinical exam or CT.', '9. Pregnant or nursing females.', '10. Unwilling or unable to follow protocol requirements.', \"11. Any condition which in the Investigator's opinion deems the participant an\", 'unsuitable candidate to receive study drug.', '12. Received an investigational agent within 30 days prior to enrollment.', '13. Trismus or compromised airway.', '14. Previous therapy to the target tumor site.', 'Study participant meets all entry criteria:', 'Yes', 'No', 'Investigator Signature:', 'Date:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 6 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'TABLE OF CONTENTS', 'SYNOPSIS', '3', '1', 'Background', '12', '1.1', 'Cancer of the Oral Cavity', '12', '1.2', 'Standard Treatment for Early Stage Cancer of the Oral Cavity', '12', '1.3', 'Photodynamic Therapy for Early Stage Head and Neck Cancer', '12', '1.4', 'Preclinical Studies with HPPH', '14', '1.5', 'Clinical Studies: HPPH', '14', '1.5.1', 'Pharmacokinetics (PK)', '14', '1.5.2', 'The HPPH Dose', '15', '1.5.3', 'The Light Fluence Rate and Dose for Early Stage Head and Neck Cancer', '15', '1.6', 'Risks and/or Benefits', '16', '2', 'Rationale', '16', '2.1', 'Rationale for Ancillary Laboratory Studies', '17', '3', 'Objectives', '17', '3.1', 'Primary Objective', '17', '3.2', 'Secondary Objectives', '17', '3.3', 'Tertiary Objective', '18', '4', 'Methodology', '18', '4.1', 'Study Design', '18', '4.1.1', 'Treatment Procedure', '19', '4.1.2', 'Post Treatment Evaluation', '20', '4.2', 'Participant Quality of Life Evaluation', '21', '4.3', 'Management of the Neck and Salvage Surgery', '21', '4.4', 'Target Accrual and Study Duration', '22', '5', 'Participant Selection', '22', '5.1', 'Inclusion Criteria', '22', '5.2', 'Exclusion Criteria', '23', '5.3', 'Inclusion of Women and Minorities', '23', '6', 'Investigational Products', '23', '6.1', 'Active Substance and Source', '23', '6.2', 'Drug Shipment', '24', '6.3', 'Storage, Preparation and Stability', '24', '6.4', 'Handling and Disposal', '25', '6.5', 'The Treatment Laser System', '25', '7', 'Treatment Plan for PDT with HPPH:', '25', '7.1', 'Dosing and Administration', '25', '7.2', 'Participant Dose Modifications', '25', '7.3', 'Duration of Treatment', '25', '7.4', 'Study Withdrawal', '26', '8', 'Study Procedures', '26', '8.1', 'Participant Randomization and Registration', '27', '8.2', 'Baseline Evaluations', '27', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 7 of 64']\n\n###\n\n", "completion": "END"}